Literature DB >> 2381443

Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome.

J Joven1, C Villabona, E Vilella, L Masana, R Albertí, M Vallés.   

Abstract

BACKGROUND AND METHODS: Patients with the nephrotic syndrome characteristically have multiple abnormalities of lipoprotein metabolism, but the cause and exact nature of these abnormalities are uncertain. In this study, we measured serum lipids and apoproteins in 57 patients with the nephrotic syndrome. We also determined the kinetic indexes of low-density lipoprotein (LDL) metabolism in six patients, and again in three of the six after recovery.
RESULTS: The patients with the nephrotic syndrome had elevated serum concentrations of cholesterol, triglycerides, and phospholipids, which were confined to the lipoproteins containing apoprotein B. The serum concentrations of high-density lipoproteins and the associated A-I and A-II apoproteins were similar in the patients with the nephrotic syndrome and normal subjects. The relative proportions of lipids and their positive association with the increased serum concentrations of apoproteins B, C-II, C-III, and E suggest quantitative rather than qualitative differences in the lipoproteins. All the patients had lipiduria, which probably reflected the excretion of high-density lipoproteins, although no intact immunoreactive apoprotein A-I was found in urine. Serum albumin concentrations were inversely related to serum lipid concentrations in the patients, the severity of the hypoalbuminemia corresponding to the degree of change in serum lipoprotein concentrations. The kinetic studies of lipoprotein metabolism revealed an overproduction of LDL apoprotein B that returned to normal after recovery.
CONCLUSIONS: The elevated serum concentrations of LDL cholesterol, other lipids, and apoprotein B in patients with uncomplicated nephrotic syndrome are due to reversible increases in lipoprotein production.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2381443     DOI: 10.1056/NEJM199008303230905

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  46 in total

1.  Apolipoprotein B attenuates albuminuria-associated cardiovascular disease in prevention of renal and vascular endstage disease (PREVEND) participants.

Authors:  James P Corsetti; Ron T Gansevoort; Stephan J L Bakker; Charles E Sparks; Priya Vart; Robin P F Dullaart
Journal:  J Am Soc Nephrol       Date:  2014-05-22       Impact factor: 10.121

Review 2.  Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.

Authors:  Nosratola D Vaziri
Journal:  Kidney Int       Date:  2016-04-26       Impact factor: 10.612

3.  Three-fold effect of lovastatin treatment on low density lipoprotein metabolism in subjects with hyperlipidemia: increase in receptor activity, decrease in apoB production, and decrease in particle affinity for the receptor. Results from a novel triple-tracer approach.

Authors:  L Berglund; J L Witztum; N F Galeano; A S Khouw; H N Ginsberg; R Ramakrishnan
Journal:  J Lipid Res       Date:  1998-04       Impact factor: 5.922

Review 4.  ACE inhibitors and proteinuria.

Authors:  R T Gansevoort; D de Zeeuw; P E de Jong
Journal:  Pharm World Sci       Date:  1996-12

5.  Apolipoprotein AII levels are associated with the UP/UCr levels in idiopathic steroid-sensitive nephrotic syndrome.

Authors:  Takahiro Kanai; Takanori Yamagata; Takane Ito; Jun Odaka; Takashi Saito; Jun Aoyagi; Mariko Y Momoi
Journal:  Clin Exp Nephrol       Date:  2014-03-15       Impact factor: 2.801

6.  Efficacy of simvastatin in children with hyperlipidemia secondary to kidney disorders.

Authors:  Silvestre García-de-la-Puente; José Luis Arredondo-García; Pedro Gutiérrez-Castrellón; Aurora Bojorquez-Ochoa; Edith Reyna Maya; María Del Pilar Pérez-Martínez
Journal:  Pediatr Nephrol       Date:  2009-02-24       Impact factor: 3.714

7.  Apolipoprotein E polymorphism and clinical course in childhood nephrotic syndrome.

Authors:  Sung-Do Kim; Il-Soo Kim; Byung-Cheol Lee; Kang-Duk Choi; Joo-Ho Chung; Chun-Gyoo Ihm; Byoung-Soo Cho
Journal:  Pediatr Nephrol       Date:  2003-02-13       Impact factor: 3.714

Review 8.  Treatment of lupus nephritis.

Authors:  Fayez F Hejaili; Louise M Moist; William F Clark
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 9.  [Pathophysiology and therapy of lipid metabolism disorders in kidney diseases].

Authors:  C J Olbricht
Journal:  Klin Wochenschr       Date:  1991-08-01

10.  A case of membranous glomerulonephritis presenting as pulmonary embolism and acute hyperlipidaemia.

Authors:  A J Hartland; P D Giles; J E Bridger; W Simmons
Journal:  J Clin Pathol       Date:  2002-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.